Around $375 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Thursday, there were a few notable insider trades.
Piper Sandler Downgrades Akouos to Neutral, Lowers Price Target to $13
Piper Sandler analyst Yasmeen Rahimi downgrades Akouos (NASDAQ:AKUS) from Overweight to Neutral and lowers the price target from $18 to $13.
William Blair Downgrades Akouos to Market Perform
William Blair analyst Sami Corwin downgrades Akouos (NASDAQ:AKUS) from Outperform to Market Perform.
Crude Oil Drops Over 2%; Akouos Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 300 points on Tuesday.
Nasdaq Rises Over 100 Points; Goldman Sachs Tops Q3 Views
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Tuesday.
Health Care Company Eli Lilly Announces Acquisition of Akouos
Eli Lilly (NYSE:LLY) has announced an acquisition of Akouos (NASDAQ:AKUS) that is expected to be completed in Q4 of 2022.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers
Akouos (NASDAQ:AKUS) shares moved upwards by 86.2% to $13.05 during Tuesday's pre-market session. The company's market cap stands at $481.5 million.
Lilly To Acquire Akouos; Acquisition Valued At $487M Plus Contingent Value Right For Aggregate Amount Of $610M
Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide
Transaction valued at approximately $487 million plus a
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
Gainers
Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
William Blair Initiates Coverage On Akouos with Outperform Rating, Announces Price Target of $12
William Blair analyst Sami Corwin initiates coverage on Akouos (NASDAQ:AKUS) with a Outperform rating and announces Price Target of $12.